leadf
logo-loader
viewCardiol Therapeutics
(
TSX:CRDLNASDAQ:CRDL
)

Cardiol announces topline results from a Phase I clinical trial of CardiolRx

Cardiol Therapeutics (TSE: CRDL- OTCQX: CRTPF) CEO David Elsley joined Steve Darling from Proactive to share news the company has announced topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx.

Elsley said the study was a placebo-controlled, double-blind study and consisted of 52 subjects ranging in age split into two groups. The study demonstrated that CardiolRx was safe and generally well-tolerated at all dose levels, with no serious adverse events reported in the study. Fifty-one of the 52 enrolled subjects completed all requirements of the protocol.

Quick facts: Cardiol Therapeutics

Follow
TSX:CRDL

Price: 5.69 CAD

Market Cap: $244.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Cardiol Therapeutics reaches company milestone as they begin trading on the...

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to bring news the company has hit a major corporate milestone as they begin trading on the Nasdaq Exchange under the ticker “CRDL” Elsley telling Proactive the company will continue to trade on the...

on 12/8/21

2 min read